Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 80425-0535

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 80425-0535). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rizatriptan Benzoate Odt 10mg #18 (Rizatriptan Benzoate Odt 10mg 80425 0535 01)

This text provides information about Rizatriptan Benzoate ODT 10mg tablet, which is compared to Maxalt MLT. It includes details such as NDC numbers, lot number, expiration date, and it is for prescription use only. The tablet is meant to be stored between 20°C and 25°C.*

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

This text describes the estimated probability of achieving an initial headache response within 2 hours based on pooled data from four placebo-controlled studies. The Kaplan-Meier plot displayed in Figure 1 illustrates the probability over time of obtaining a headache response following treatment with rizatriptan benzoate or placebo. Patients who took additional treatment or did not achieve a headache response before 2 hours were censored at that time point.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)

This is a description of a Kaplan-Meier plot showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate Tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in pooled studies 1, 2, 3, and 4. The plot includes patients who had a headache response at 2 hours and those who had no response to the initial dose. Remedication was not allowed within 2 hours post-dose. The data was obtained from 4 placebo-controlled outpatient clinical trials.*

FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

The text provides information about the estimated probability of achieving an initial headache response with Rizatriptan Benzoate Orally Disintegrating Tablets within 2 hours based on Pooled Studies 5 and 6. It discusses the data from placebo-controlled outpatient trials showing the efficacy of the treatment. The figure displays the Kaplan-Meier plot of the probability over time of obtaining a headache response after administering the tablets.*

FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose O (Rizatriptan Fig4)

Figure 4 provides the estimated probability of patients taking a second dose of Rizatriptan Benzoate Orally Disintegrating Tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in Pooled Studies 5 and 6. The graph shows the percentage of patients opting for a second dose over the hours post-dose, based on data obtained in two placebo-controlled outpatient clinical trials (Studies 3 and 6). Patients who did not use additional treatments were censored at 24 hours. The plot includes patients who had a headache response at 2 hours and those who had no response to the initial dose.*

FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

This is a figure from a study showing the percentage of patients reporting no headache pain by 2 hours post-dose in Study 7. The graph compares the effectiveness of Rizatriptan Benzoate OD Tablets and Placebo over time. Time is shown in hours post Stage 2 Dose on the X-axis and the percentage of patients on the Y-axis.*

FDA Label Image

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.